RCS - StageZero Life - StageZero Life Sciences Launches AVRT in the UK
01/04/2022 08:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA8688Ga&default-theme=true
RNS Number : 8688G StageZero Life Sciences 01 April 2022
StageZero Life Sciences Launches AVRT in the UK
Innovative program helps identify and address the early warning signs of
cancer and chronic disease
TORONTO, ON / ACCESSWIRE / March 31, 2022 / StageZero Life Sciences, Ltd.
(https://pr.report/wPb1cC2D) (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the
"Company"), a vertically integrated healthcare company devoted to improving
the early detection and management of cancer and other chronic diseases
through leading-edge molecular diagnostics and clinical interventions, today
announced the launch of the AVRT™ program for patients living in the United
Kingdom. AVRT is an innovative physician-led program aimed at proactively
identifying and managing the early warning signs of cancer and chronic
disease. Today's announcement builds on the availability of the AVRT program
in the US, and the Care Oncology Clinic service that is currently available
within the UK, Europe, the US, and Canada.
"A staggering 1 in every 2 people born in the UK after 1960 will be diagnosed
with cancer during their lifetime, but it is less well known that 40% of these
diagnoses are linked to modifiable risk factors and, therefore, may be
preventable with the correct lifestyle modifications.(1,2) However, people
often don't know how to go about starting to make those changes," said Padman
Vamadevan, M.D., Clinical Director of Global Product Development at StageZero
Life Sciences. "That's where the AVRT program comes into its own: our expert
clinicians specialize in identifying and managing the early warning signs of
cancer and other chronic diseases. Whether an individual has a strong family
history of cancer, diabetes, cardiovascular disease, or another chronic
condition, or is simply concerned about their current wellbeing, our
physicians work with people one-on-one to help guide them to optimize their
health in a proportionate and tolerable manner."
Created by the physicians and scientists who developed the groundbreaking COC
Protocol, AVRT employs a similar approach by identifying the inflammatory and
metabolic pathways that may increase the risk of developing cancer and chronic
disease, and facilitating personalized early interventions to reduce the risk
of disease onset or progression. The AVRT program includes:
· Comprehensive digital health evaluations;
· Proprietary panels of blood tests that measure biomarkers of
inflammation and metabolic dysfunction;
· In-depth initial consultations with expert clinicians in the
field of metabolic health;
· Personalized care plans with actionable insights; and
· Regular physician interval and follow-up appointments to maintain
engagement and track progress.
The program is designed to empower users to take control of their health by
offering readouts of all their AVRT data, enabling them to track their
progress and visualize any benefits of the changes they make in real time, as
well as continuous access to curated resources to ensure patients are
supported to make consistently positive health choices. The service is
available both in person at premises in Harley Street, London, UK, and
remotely via telemedicine.
"Launching the AVRT program in the UK continues the momentum started six
months ago with the acquisition of Care Oncology and follows on the launch of
AVRT in the US this quarter and the expansion of the COC Protocol program for
patients with cancer. This program expansion directly contributes to our
corporate long-term growth initiatives of broadening, deepening, and expanding
our offerings and interaction between the programs," said James Howard-Tripp,
Chairman and CEO of StageZero Life Sciences.
To learn more about AVRT, please visit avrtnow.co.uk
(https://pr.report/Sg6jwKdk) in the UK and avrtnow.com
(https://pr.report/TwtlLygY) in the US and Canada.
References
1. Cancer Research UK. Data and Statistics. Accessed March 30, 2022.
https://www.cancerresearchuk.org/health-professional/data-and-statistics
(https://pr.report/sFLY4Azw) .
2. American Institute of Cancer Research. Media Library. Accessed March
30, 2022.
https://www.aicr.org/resources/media-library/around-40-of-cancers-can-be-prevented/
(https://pr.report/8kQWqXFa) .
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company
dedicated to improving the early detection and management of cancer and other
chronic diseases through next-generation diagnostics and unique telehealth
programs that provide clinical interventions to assist patients who currently
have cancer (COC Protocol) as well as help patients reduce the risk of
developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA
multi-cancer panel for simultaneously screening for multiple cancers from a
single sample of blood with high sensitivity and specificity for each cancer.
Aristotle® uses mRNA technology to identify the molecular signatures of
multiple cancer types and is built on the Company's patented technology
platform, the Sentinel Principle. This underlying technology has been
validated in more than 9,000 patients and used by more than 100,000 patients
in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC
Protocol) for people diagnosed with cancer of any type or stage. Developed by
scientists and oncologists, the COC Protocol is intended for adjunctive
administration alongside standard-of-care cancer therapy. It is an
individualized therapeutic approach which seeks to simultaneously target
multiple metabolic cancer pathways. The aim is to restrict cancer cell energy
supply and use, which may make it more difficult overall for cancer cells to
survive, grow and adapt to changing conditions in the body. As a result, such
cells can potentially become more vulnerable to attack from cell-killing
therapies such as radiotherapy and chemotherapy. Its patented COC Protocol
incorporates a multifaceted approach, supported by peer-reviewed scientific
studies, which highlight the potential of certain treatments to target the
specific energy requirements of cancer cells, impacting their ability to grow
and multiply.
AVRT is a physician-led telehealth program for identifying and managing the
early warning signs of cancer and chronic disease. Our program includes: a
comprehensive online health evaluation; blood tests to measure markers of
inflammation and metabolism; an in-depth initial physician consultation;
regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®,
BreastSentry™, and the Prostate Health Index) are processed at the Company's
clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA
certified high-complexity reference laboratory in Richmond, Virginia. In
addition, the Company is also leveraging its specialty in polymerase chain
reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and
Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol
SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words
such as "expects", "will" and similar expressions, which reflect the Company's
current expectations regarding future events. The forward-looking statements
involve risks and uncertainties that could cause the Company's actual events
to differ materially from those projected herein. Investors should consult the
Company's ongoing quarterly filings and annual reports for additional
information on risks and uncertainties relating to these forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. The Company disclaims any obligation to update these
forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com (mailto:rgreco@stagezerols.com)
SOURCE: StageZero Life Sciences Ltd
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUARORUSUOOUR